The role of hypertension and renin-angiotensin-aldosterone system inhibitors in bleomycin-induced lung injury

Publication date: Available online 9 October 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Ryujiro Hara, Makoto Onizuka, Sawako Shiraiwa, Kaito Harada, Yasuyuki Aoyama, Daisuke Ogiya, Masako Toyosaki, Rikio Suzuki, Sinichiro Machida, Ken Ohmachi, Yoshiaki Ogawa, Hiroshi Kawada, Shigeki Watanabe, Akira Miyajima, Ryota Masuda, Masayuki Iwazaki, Mikio Mikami, Takashi Koike, Hiroyuki Mochizuki, Kiyoshi Ando
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

Publication date: Available online 18 August 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Kadriye Bahriye Payzin, Kaan Savasoglu, Inci Alacacioglu, Elif Ebru Dalgic, Betul Bolat Kucukzeybek, Aylin Orgen Calli, Sadi Bener, Serdar Payzin
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 18 August 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Kadriye Bahriye Payzin, Kaan Savasoglu, Inci Alacacioglu, Elif Ebru Dalgic, Betul Bolat Kucukzeybek, Aylin Orgen Calli, Sadi Bener, Serdar Payzin
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
This prospective study assessed the prevalence of pulmonary hypertension (PHT) related to chronic myeloproliferative neoplasms (CMPNs) and evaluated the impact of PHT on survival during long-term follow-up. In a large group of BCR-ABL1 –negative CMPN patients, there was a low prevalence of PHT. The impact of PHT on survival was negligible.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
RARITAN, NJ, February 10, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX® (daratumumab) in combination with Kyprolis® (carfilzomib) and dexamethasone (DKd) for relapsed/refractory multiple myeloma. The sBLA is supported by results from the Phase 3 CANDOR study, which compared treatment with DKd to carfilzomib and dexamethasone (Kd) in patients with multiple myeloma who relapsed after one to three prior lines of therapy. “Wh...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
This study adds to the body of evidence in describing incidence and type of cardiac events experienced by an allogeneic and autologous HSCT population at one institution from 2012-2017. Sixty-five patients (9.8%) experienced cardiac events, including atrial arrhythmia (N = 39), acute heart failure (N = 9), acute coronary syndrome (N = 7), new onset hypertension (N = 9), with a few instances of bradycardia, ventricular arrhythmia, pericardial effusion, and pericarditis. Our multivariable regression analysis identified age (older), creatinine (higher) and history of coronary artery disease to significantly correlate with ris...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Carfilzomib (CFZ) is a proteasome inhibitor associated with cardiovascular (CV) adverse events (AEs) such as hypertension (HTN), cardiac dysfunction and thrombotic events such as venous thromboemolism and thrombotic microangiopathy (TMA). Endothelial dysfunction is a major mediating mechanism in these complications and may be affected by proteasome inhibition caused by CFZ.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Publication date: Available online 13 May 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Matthew Austin, Peter J. Quesenberry, Corey E. Ventetuolo, Olin Liang, John L. ReaganAbstractMyelofibrosis (MF), a rare disorder characterized by bone marrow fibrosis, has been implicated as a cause of pulmonary hypertension (PH). To date, studies examining this association have not looked at the impact of PH on survival in MF. In this single center, retrospective chart review we identified 65 patients with biopsy proven primary and secondary myelofibrosis of whom 31 underwent transthoracic echocardiography. After account...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
In this study, we reviewed major human studies on the health risks of radiation exposure and showed that sex-related factors may potentially influence the long-term response to radiation exposure. Available data suggest that long-term radiosensitivity in women is higher than that in men who receive a comparable dose of radiation. The report on the biological effects of ionizing radiation (BEIR VII) published in 2006 by the National Academy of Sciences, United States emphasized that women may be at significantly greater risk of suffering and dying from radiation-induced cancer than men exposed to the same dose of radiation....
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
Conclusions Epidemiological studies have repeatedly helped identify definitive triggers for several diseases. As highlighted in this perspective report, previous studies strongly argue for the interplay between intrinsic factors and putative preventable extrinsic triggers/promoters for CTCL. Given the evidence of geographical regional clustering of CTCL patients, CTCL occurrence in unrelated family members and recent evidence implicating S. aureus in the pathogenesis/progression of CTCL, more research is needed to decipher the precise mechanism by which specific environmental exposures may be driving the pathogenesis of t...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
A forty four year-old woman with history of hypertension presented with shortness of breath, lower extremity swelling and foamy dark urine that developed in a matter of a few weeks.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
More News: Cancer & Oncology | Hypertension | Leukemia | Lymphoma | Myeloma